Filing Flows › Aurinia Pharmaceuticals (AUPH) › Q2 2026
Aurinia Pharmaceuticals (AUPH) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Aurinia Pharmaceuticals (AUPH) reported revenue of $83.2M for the second quarter 2026 (Q2 2026), +19% from a year earlier and +7% from the quarter before. Operating margin was 55.7%, net earnings $37.4M (45.0% of revenue).
Aurinia Pharmaceuticals, Q2 2026: revenue $83.2M (+19% year over year), operating margin 55.7%, net earnings $37.4M, operating cash flow $52.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $83.2M | +7% | +19% |
| Operating profit | $46.3M | +12% | +131% |
| Net earnings | $37.4M | +9% | +74% |
| Operating cash flow | $52.6M | +61% | +19% |
What changed
Revenue was $83.2M in Q2 2026, up 19% year over year and up 7% from the previous quarter. Net product sales was the largest line at 95% of revenue. Net product sales added $12.8M year over year (up 19%), 97% of the total change.
Operating profit was $46.3M, a 55.7% margin (up 27.0 points year over year). Of the extra revenue versus Q2 2025, 199% reached operating profit, above the 29% margin then. Total costs fell 26% while revenue rose 19%. Net earnings were $37.4M, up 74% year over year. The effective tax rate was 23.3%.
Operating cash flow was $52.6M (up 19% year over year), 140% of net earnings. Non-cash charges added back $4.8M of depreciation and amortization and $2.8M of share-based compensation. Working capital and other items added $7.5M.
Questions
What was Aurinia Pharmaceuticals' revenue in the second quarter 2026?
Aurinia Pharmaceuticals (AUPH) reported revenue of $83.2M for the second quarter 2026 (Q2 2026), +19% from a year earlier and +7% from the quarter before.
Was Aurinia Pharmaceuticals profitable in the second quarter 2026?
Operating profit was $46.3M (55.7% of revenue) and net earnings $37.4M.